Achieve Life Sciences (SP4P) Q1 2026 Earnings Report

The call conveyed strong positive momentum: a substantial financing, experienced new leadership and commercial hires, U.S. manufacturing partnership with initial batches, robust Phase III efficacy (notably 32.4% vs 6% in hard-to-treat patients) and supportive mechanistic/tolerability data. The principal negatives are an anticipated FDA CRL tied to a third-party manufacturer OAI, requiring an NDA resubmission in Q4 2026 and introducing execution risk around the manufacturing tech transfer to Adare and timing uncertainty. Overall, the company appears well capitalized and operationally proactive to address the delays and pursue a planned H1 2027 launch, but near-term regulatory and manufacturing execution risks remain.

Achieve guided that it expects a complete response letter on or by its June 20, 2026 PDUFA date and plans to resubmit the NDA in Q4 2026 naming Adare as primary manufacturer (first Adare engineering batch completed in Q1 2026) with a targeted commercial launch in H1 2027; the company also expects to initiate the ORCA‑V2 vaping Phase III this year under its CNPV and breakthrough designations. Financially, the company closed a financing providing $180 million upfront plus up to $174 million of milestone-based warrants (exercisable any time prior to and up to 20 trading days following FDA approval). Key clinical/operational metrics cited include analysis of >1,600 Phase III participants, two Phase III double‑blind, placebo‑controlled trials in which both 6‑ and 12‑week courses were statistically significant, planned 52‑week safety/efficacy data later this year, and subgroup results showing 12‑week cytisinicline continuous abstinence of 32.4% versus 6% on placebo (OR 7.5); Achieve said it will commercialize independently with a scalable field force and believes its IP extends into the late 2030s/2040s.